Resistant mechanisms of doxorubicin

doi:10.3760/cma.j.issn.1673-422X.2013.12.002

Abstract

Abstract: Doxorubicin is widely used in chemotherapy of breast cancer and many other cancers. However, doxorubicin resistance restricts its use to some extent. The mechanisms of doxorubicin resistance may involve transport protein, apoptosis protein, DNA repair function, enzyme and other factors. Researches about reversing doxorubicin resistance are ongoing and provide some effective therapeutic regimens to overcome doxorubicin resistance clinically. But the specific mechanism of doxorubicin resistance is yet to be elucidated. It is expected that more reasonable and effective countermeasures will be put forward to improve the theraputical effect of doxorubicin.

Key words: Drug resistance, neoplasm, Doxorubicin

XIAN Zhi-Rong, ZHANG Guo-Jun. Resistant mechanisms of doxorubicin[J]. Journal of International Oncology, 2013, 40(12): 886-889.

References

［1］ Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta, 2009, 1794(5): 860871. ［2］ Xu HB, Li L, Fu J, et al. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by βelemene. Pharmacology, 2012, 89(56): 303312. ［3］ Zhu MM, Tong JL, Xu Q, et al. Increased JNK1 signaling pathway is responsible for ABCG2mediated multidrug resistance in human colon cancer. PLoS One, 2012, 7(8): e41763. ［4］ O′Malley FP, Chia S, Tu D, et al. Topoisomerase Ⅱ alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst, 2009， 101(9): 644650. ［5］ Du Y, Zhou Q, Yin W, et al. The role of topoisomerase Ⅱα in predicting sensitivity to anthracyclines in breast cancer patients: a metaanalysis of published literatures. Breast Cancer Res Treat, 2011, 129(3): 839848. ［6］ Taylor JR, Lehmann BD, Chappell WH, et al. Cooperative effects of Akt1 and Raf1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget, 2011, 2(8): 610626. ［7］ Trape AP, Katayama ML, Roela RA, et al. Gene expression profile in response to doxorubicinrapamycin combined treatment of HER2overexpressing human mammary epithelial cell lines. Mol Cancer Ther, 2012, 11(2): 464474. ［8］ El Azreq MA, Naci D, Aoudjit F. Collagen/β1 integrin signaling upregulates the ABCC1/MRP1 transporter in an ERK/MAPKdependent manner. Mol Biol Cell, 2012, 23(17): 34733484. ［9］ Shen H, Xu W, Luo W, et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB1 nuclear translocation in Bcell lymphoma. Exp Hematol, 2011, 39(5): 558569. ［10］ Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D,Llactidecoglycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm, 2011, 8(3): 852866. ［11］ Wang MY, Chen PS, Prakash E, et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant upregulation of BclxL and cIAP1. Cancer Res, 2009, 69(8): 34823491. ［12］ Knappskog S, Chrisanthar R, Lokkevik E, et al. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res, 2012, 14(2): R47. ［13］ Wang X, Wu X, Wang C, et al. Transcriptional suppression of breast cancer resistance protein (BCRP) by wildtype p53 through the NFkappaB pathway in MCF7 cells. FEBS Lett, 2010, 584(15): 33923397. ［14］ Tian B, Liu J, Liu B, et al. p53 suppresses lung resistancerelated protein expression through Ybox binding protein 1 in the MCF7 breast tumor cell line. J Cell Physiol, 2011, 226(12): 34333441. ［15］ Pardee TS. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. PLoS One, 2012, 7(8): e43185. ［16］ Hilton J, Weberpals J, Lorimer I, et al. BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: an exploratory analysis. Oncol Lett, 2012, 4(1): 141145. ［17］ Zhang Y, Wang H, Wei L, et al. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat, 2010, 123(3): 679689. ［18］ Hartz AM, Madole EK, Miller DS, et al. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3kinase/Akt/glycogen synthase kinase 3 downregulates bloodbrain barrier breast cancer resistance protein. J Pharmacol Exp Ther, 2010, 334(2): 467476. ［19］ Zhu X, He Z, Wu J, et al. A marine anthraquinone SZ685C overrides adriamycinresistance in breast cancer cells through suppressing Akt signaling. Mar Drugs, 2012, 10(4): 694711. ［20］ Donmez Y, Akhmetova L, Iseri OD, et al. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicinresistant MCF7 cells. Cancer Chemother Pharmacol, 2011, 67(4): 823828. ［21］ Shen Y, Chu Y, Yang Y, et al. Mitochondrial localization of Pglycoprotein in the human breast cancer cell line MCF7/ADM and its functional characterization. Oncol Rep, 2012, 27(5): 15351540. ［22］ Liu G, Wang R, Wang Y, et al. Ethacrynic acid oxadiazole analogues induce apoptosis in malignant hematological cells through downregulation of Mcl1 and cFLIP which was attenuated by GSTP11. Mol Cancer Ther, 2013, 12(9): 111. ［23］ Wang F, Liu HM, Irwin MG, et al. Role of protein kinase C beta2 activation in TNFalphainduced human vascular endothelial cell apoptosis. Can J Physiol Pharmacol, 2009, 87(3): 221229.

[1]	Chu Chaonan, Huang Qi. Comparison of the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum resistant ovarian cancer [J]. Journal of International Oncology, 2019, 46(1): 32-35.
[2]	FAN Hua, LIU Min-Li, CHANG Qi, LIU Yong-Feng, SUN Xue-Jun, ZHANG Sheng-Jun. Study of transferrin modified doxorubicin liposome targeted to inhibit proliferation of breast cancer cells [J]. Journal of International Oncology, 2016, 43(8): 641-645.
[3]	Cheng Liying, Sun Tao, Chen Wenqiang, Meng Qingsong. Smac playing vital role in enhancing the sensitivity of cyclophosphamide and doxorubicin in breast cancer MCF-7 cell line [J]. Journal of International Oncology, 2015, 42(12): 881-885.